Is Chonluten FDA approved?

Chonluten is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is TB-500 FDA approved?

TB-500 is not FDA approved and restricted from compounding. It is discussed for research and educational purposes only, not as medical guidance.

How is Chonluten administered in research settings?

In research settings, Chonluten is typically administered via the oral or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is TB-500 administered in research settings?

In research settings, TB-500 is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Chonluten vs TB-500

Peptide Comparison

Chonluten vs TB-500

Name: Chonluten vs TB-500 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Chonluten

Bronchogen

RecoveryNot EvaluatedResearch Only

Half-life: Unknown

2 providers listed

Full Chonluten profile →

TB-500

thymosin beta 4

RecoveryBanned from CompoundingResearch Only

Half-life: 5–7 days

402 providers listed

Full TB-500 profile →

Bottom line

Chonluten and TB-500 target different goals — Chonluten for bronchial repair, TB-500 for actin binding and cellular migration facilitation — core mechanism driving tissue repair. They're compared here for reference, not as direct substitutes.

Quick Verdict

Chonluten

Evidence

Review-level

Half-life

Unknown

TB-500

Evidence

Preclinical

Half-life

5–7 days

Different Goals

Chonluten and TB-500 target different goals — Chonluten for Immune & Thymic, TB-500 for Tissue Repair. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

Chonluten

TB-500

Mechanism Family

Immune & Thymic

Tissue Repair

Half-life

Unknown

5–7 days

FDA Status

not evaluated

banned from compounding

Admin Routes

oral, subcutaneous

subcutaneous

Availability

Research Only

Providers

2 listed

402 listed

FDA Update

—

Dec 2023

Avail. Notes

Russian peptide bioregulator (Glu-Asp-Lys) from Khavinson Institute. Developed for lung health. No FDA approval, no NDA or IND. Not on any FDA list. Research chemical in US.

Not FDA-approved; WADA prohibited (S2). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023, alongside BPC-157. The FDA did not reclassify it to "Category 1" in February 2026 (that was an HHS announcement of intent, not an FDA action). In April 2026 the FDA removed the thymosin β4 fragment (TB-500) from Category 2 because the nomination was withdrawn — this does not authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review TB-500 on July 23–24, 2026.

Research Evidence

Chonluten

Review-levelReview · 2 key studies · most recent 2022

TB-500

PreclinicalReview · 3 key studies · most recent 2019

Research Citations

Chonluten

Review2022 · International Journal of Molecular Sciences

Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

TB-500

Review2019 · Canadian Journal of Physiology and Pharmacology

Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

Animal2013 · Kidney International

Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis

Animal2003 · Wound Repair and Regeneration

Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…

About Chonluten

Tripeptide bioregulator targeting bronchial epithelial cells; normalizes gene expression in bronchial tissue; promotes epithelial regeneration

Research Areas

bronchial repairlung tissue regenerationrespiratory anti-inflammatory

About TB-500

TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.

Research Areas

actin binding and cellular migration facilitation — core mechanism driving tissue repairwound healing and anti-inflammatory effects across muscle, tendon, and cardiac tissuethymosin beta-4 C-terminal fragment — angiogenesis and systemic distributionsubcutaneous injection — frequently combined with BPC-157 in recovery research stacks

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Chonluten

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

TB-500

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Regulatory Notes

global — WADA

TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.

source

Used Together?

TB-500

BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.

Price (per mg)

Chonluten

$2.70/mg

$2.00 – $3.10 range

8 vendors

View price index →Find providers →

TB-500

$7.00/mg

$5.00 – $10.00 range

85 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Chonluten

2 listed

Browse directory →

Providers offering

TB-500

402 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Chonluten vs TB-500 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/chonluten/tb-500

https://peptidebase.io/peptides/compare/chonluten/tb-500 Methodology License Download JSON Download CSV